MediWound

MediWound presented its bromelain platform at the H.C. Wainwright conference, highlighting NexoBrid revenue potential and the upcoming VALUE phase III study for EscharEx as key drivers. The VALUE study (216 patients) includes an interim analysis at ~65% recruitment; various sample-size adjustments are possible, and topline data are expected about three months after the interim analysis. The company is expanding production capacity, expects European approval in mid‑2027, and points to commercial progress with NexoBrid as well as a BARDA-linked partnership with Vericel. » More on de.investing.com

MediWound has called an extraordinary general meeting for Feb. 19, 2026, and on Jan. 15, 2026 filed the related notice and a proxy statement with the SEC. Registered shareholders will receive voting materials and a proxy card. The filings give meeting details but do not disclose specific agenda items; the documents refer to existing registration statements on Forms S-8 and F-3. » More on de.investing.com

A prospective study at Sheba Medical Center found that MediWound’s enzymatic preparation NexoBrid reduced the pigmented wound surface by an average of 92.5% in 15 patients (96% for abrasion injuries, 84% for blast injuries). The treatment was administered at the bedside under sedation within 24 hours and showed no treatment-related adverse events in early follow-up. MediWound recently raised around $30 million via a direct offering, received approval in Australia and is planning production and capacity expansions; one analyst raised the price target. » More on de.investing.com